📰 Genoscience Pharma News
Page 2 - Genoscience Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genoscience Pharma. Real-time updates on events, politics, business and more.
July 9, 2023
Genfit (OTCMKTS:GNFTF – Free Report) is one of 374 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Genfit to related businesses based on the strength of its institutional ownership, valuation, analyst recommendations, risk, earnings, dividends and profitability. Valuation & Earnings This table compares Genfit and its […]
July 9, 2023
Windtree Therapeutics (NASDAQ:WINT – Free Report) and Genfit (NASDAQ:GNFT – Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk. Institutional and Insider Ownership 22.0% of Windtree Therapeutics shares are […]
July 7, 2023
Windtree Therapeutics (NASDAQ:WINT – Free Report) and Genfit (NASDAQ:GNFT – Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership. Risk and Volatility Windtree Therapeutics has a beta of 0.17, […]
July 6, 2023
Genfit (OTCMKTS:GNFTF – Free Report) is one of 365 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Genfit to related businesses based on the strength of its analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk. Profitability This table compares Genfit and its rivals’ net […]
July 3, 2023
Genfit (OTCMKTS:GNFTF – Free Report) is one of 370 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Genfit to related businesses based on the strength of its earnings, valuation, risk, dividends, profitability, institutional ownership and analyst recommendations. Insider and Institutional Ownership 11.1% of Genfit shares are […]
July 1, 2023
Genfit (OTCMKTS:GNFTF – Free Report) is one of 400 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Genfit to similar companies based on the strength of its valuation, institutional ownership, earnings, dividends, profitability, analyst recommendations and risk. Institutional and Insider Ownership 11.1% of Genfit shares are […]
June 7, 2023
The prevalence of cholangiocarcinoma has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of cholangiocarcinoma and the
June 7, 2023
/PRNewswire/ -- Cholangiocarcinoma Pipeline Insight – 2023 report provides comprehensive global coverage of pipeline cholangiocarcinoma therapies in various...
November 17, 2022
Phase 3 data for elafibranor in primary biliary cholangitis (PBC) expected in 2Q23Expanded pipeline now covers five therapeutic areas with high unmet...
September 29, 2022
29.09.2022 - Lille (France), Cambridge (Massachusetts, United States), September 29, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today ... Seite 1